For the quarter ending 2026-03-31, LFMD had $8,910,972 increase in cash & cash equivalents over the period. -$9,506,038 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | - | -4,670,027 | 346,850 |
| Amortization of debt discount | - | 33,481 | 200,888 |
| Net loss from continuing operations | 8,872,596 | - | - |
| Amortization of capitalized software | -5,412,202 | 2,459,534 | 4,627,520 |
| Amortization of intangibles | -743,421 | 269,450 | 505,888 |
| Loss on debt extinguishment | - | -1,155,851 | - |
| Accretion of consideration payable | - | - | 0 |
| Depreciation of fixed assets | -320,111 | 262,747 | 346,822 |
| Noncash operating lease expense | -608,837 | 243,915 | 577,689 |
| Stock compensation expense | -6,392,273 | 3,198,036 | 4,643,142 |
| Accounts receivable | 2,159,603 | -722,079 | -887,684 |
| Product deposit | -318,447 | 119,518 | 210,237 |
| Inventory | -231,464 | 181,027 | 453,997 |
| Other current assets | 628,672 | 1,287,639 | -707,257 |
| Operating lease liabilities | 97,675 | -49,673 | -198,901 |
| Deferred revenue | 6,479,475 | -2,579,515 | -2,690,893 |
| Accounts payable | 3,958,717 | -4,738,135 | 8,283,386 |
| Accrued expenses | 2,906 | 5,133,305 | -5,865,264 |
| Net cash provided by operating activities of continuing operations | 444,624 | - | - |
| Net cash provided by operating activities | -11,116,074 | -147,136 | 11,707,834 |
| Cash paid for capitalized software costs | -6,494,603 | 2,797,222 | 5,648,965 |
| Purchase of equipment | -1,610,036 | 797,258 | 917,956 |
| Purchase of intangible assets | - | - | 0 |
| Net cash used in investing activities of continuing operations | -2,056,762 | - | - |
| Net cash used in investing activities | 8,104,639 | -3,594,480 | -6,566,921 |
| Repayment of notes payable, net of prepayment penalty | - | - | 0 |
| Repayment of debt instruments | - | 16,667,433 | 2,052,288 |
| Distributions to non-controlling interest | - | 449,539 | 312,119 |
| Sale of common stock under atm, net | - | 8,721,717 | - |
| Preferred stock dividends | -1,553,125 | 776,563 | 1,553,125 |
| Cash proceeds from exercise of warrants | - | 464,950 | - |
| Cash proceeds from exercise of options | 74,570 | 5,950 | 0 |
| Contingent consideration payments for resumebuild acquisition | - | - | 0 |
| Net cash used in financing activities of continuing operations | -696,043 | - | - |
| Net cash used in financing activities | 11,922,407 | -8,700,918 | -3,917,532 |
| Net decrease in cash | 8,910,972 | -12,442,534 | 1,223,381 |
| Cash at beginning of period | 23,785,771 | 35,004,924 | - |
| Cash at end of period | 34,478,137 | 23,785,771 | - |
| Cash of continuing operations at end of period | 34,478,137 | - | - |
LifeMD, Inc. (LFMD)
LifeMD, Inc. (LFMD)